PURPOSE: This study assessed the trial of boost intracavitary brachytherapy (ICBT) for the @entity1 of @entity5 with residual malignant cells detected at the final stage of ICBT. MATERIAL AND METHODS: This is a retrospective analysis of 75 @entity1 with @entity5 treated radically with external beam radiotherapy and high-dose-rate intracavitary brachytherapy between August 2004 and December 2008. Eighteen @entity1 (24%) out of 75 received one additional ICBT and five @entity1 (7%) had two additional ICBT. All 75 @entity1 were retrospectively analyzed. The median follow-up time was 30 months. The median age was 59 years (range 28-85 years). There were 12 @entity1 (16%) in stage IB, 27 (36%) stage II, 22 (29%) stage III, and 14 (19%) stage IV. RESULTS: The 5-year overall survival rate was 65%. @entity1503 greater than grade 2 occurred in 12 @entity1 (16%). Of these, only two @entity1 received on additional ICBT. No significant difference was found in grade 3 @entity137 between @entity1 who did and did not receive additional ICBT (p = 0.8). CONCLUSIONS: The method to perform dose escalation should be examined depending on the treatment response.

A study of high-dose-rate intracavitary brachytherapy boost for curative XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Non-hematological toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer', 'uterine cervical cancer']
@entity5 :: (MESH:D009369,Disease) :: ['treatment of uterine cervical cancer']
